Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Iclepertin on QT Interval
NCT06070597Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iclepertin in schizophrenia (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: QTcF change from baseline matched to the plasma concentration of iclepertin up to 12 days. Started Jan 2024; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06070597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070597.